Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR-1 and ...

Nasal polyps are noncancerous soft tissue growths that form in your nasal passages and sinuses. They’re often a result of inflammation from sinusitis, allergens, or other issues. Experts don’t know ...

Nasal polyps can be a persistent issue for individuals suffering from chronic sinusitis, allergies, or fungal infections, often leading to breathing difficulties and discomfort. When medications and ...

Bruce Black is no stranger to sinus trouble. He’s had it for much of his adult life, thanks to hay fever, asthma, and nasal polyps. Nasal polyps are teardrop-shaped growths that can form anywhere in ...

A study of the nasal microbiome helped researchers predict recurrent polyps in chronic rhinosinusitis patients with more than 90% accuracy, based on data from 85 individuals. Chronic rhinosinusitis ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

Amgen (AMGN) and AstraZeneca (AZN) are approaching a potential catalyst event on October 19, when the FDA will rule on Tezspire for treating chronic rhinosinusitis with nasal polyps (CRSwNP). If ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and safety ...